A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
A cannabinoid receptor modulator is a compound that bind to the cannabinoid receptors, which are receptors in the human body that regulate multiple physiological responses, including pain sensation, mood regulation, and appetite. The two main targets of cannabinoid receptors modulators are cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2). By stimulating or inhibiting these receptors, the modulators can achieve different therapeutic effects, such as relieving pain, reducing vomiting, improving appetite and maintaining muscle tone. Dronabinol, nabiximol, cannabidiol and nabilone are cannabinoid receptor modulators marketed as drugs for various therapeutic uses. These drugs also share some common adverse effects, including dizziness, headache, alteration in mental state, and diarrhoea. Recent research studies have explored other therapeutic potentials of the modulators, such as the antitumor effect of cannabidiol. Other cannabinoid receptor modulators are also under investigations.
=== Lawn bowls === Men's singles champion – Matt Berry (Pringle Park Bowling Club) Men's pair champions – Jamie Hill (Mt Albert Bowling Club), Lance Pascoe (Elmwood Park Bowling Club) (skip) Men's fours champions – Mike Galloway (skip), David Clark, Martin Dixon and Steve Fisher Women's singles champion – Debbie White (Hinuera Bowling Club) Women's pair champions – Lisa Prideaux (Auckland Bowling Club), Olivia Bloomfield (New Lynn Bowling Club) (skip) Women's fours champions – Val Smith (skip), Ashleigh Jeffcoat, Kimberley Hemingway and Debbie White
== Other uses == French Defence (Encyclopaedia of Chess Openings code) Combat 18, a British neo-Nazi organisation 18th century (1701–1800 AD) Android 18, character from Dragon Ball Franchise Bill C-18, Canada's Online News Act
Sources: en.wikipedia.org
=== Gastrointestinal tract === In the gastrointestinal tract, KOR is expressed on myenteric and submucosal plexus neurons, where they modulate intestinal motility and secretion. Both KOR and MOR mRNAs are expressed in all investigated gastrointestinal regions in one study, with the stomach and proximal colon displaying the highest expression levels, and the duodenum exhibiting the lowest. KOR in the proximal colon represented 40% of the amount found in the brain. A higher number of neurons expressing KOR-like immunoreactivity are visualized in the myenteric plexus with a smaller number in the submucosal plexus, unlike the distribution pattern of MORs.
I am patriot enough to take pains to bring this useful invention into fashion in England, and I should not fail to write to some of our doctors very particularly about it if I knew any one of them that I thought had virtue enough to destroy such a considerable branch of their revenue for the good of mankind, but that distemper is too beneficial to them not to expose to all their resentment the hardy wight that should undertake to put an end to it. Perhaps if I live to return I may, however, have courage to war with them.
They argued that the game simultaneously presents the player with numerous opportunities for action while restricting how its narrative can progress. This tension becomes explicit during Jack's confrontation with Ryan: after the player has spent much of the game directly controlling Jack, control is removed while Jack is compelled to kill Ryan. Aldred and Greenspan interpreted the sequence as exposing a distinction between the player's experience of autonomy and the predetermined structures governing both Jack and the player, and related this contradiction to the game's broader critique of technological progress and individual freedom. Stefan Schubert connected the same sequence to the game's use of Objectivism. He argued that Atlas initially resembles a conventional video-game guide, directing the player's actions in a manner that players have been conditioned by other games to accept without questioning. The revelation that Jack has been compelled to obey Atlas therefore operates on both a narrative and a metatextual level: Jack discovers the limits of his own autonomy while the player is made aware of having voluntarily followed substantially the same instructions. Schubert nevertheless rejected a simple conclusion that BioShock presents all choice as meaningless. He contrasted the predetermined confrontation with Ryan with the player's treatment of the Little Sisters, which can alter the game's ending, and argued that the game instead presents agency as limited and internally contradictory.
=== Works cited === Edwards, Clive A.; Bohlen, P. J. (1996). Biology and Ecology of Earthworms. Springer Science & Business Media. ISBN 978-0-412-56160-3. Sims, Reginald William; Gerard, B (1985). Earthworms: Keys and Notes for the Identification and Study of the Species. London: Published for The Linnean Society of London and the Estuarine and Brackish-Water Sciences Association by E. J. Brill/Dr. W. Backhuys.
Sources: en.wikipedia.org
Trump further announced that month a plan for a new fleet of naval vessels, to be called Trump-class battleships, although battleships have long been obsolete in naval warfare and the Navy's last one in service was decommissioned in 1992. For many years, the National Park Service's annual general pass depicted natural landscapes, but the new 2026 pass design for U.S. residents has a photo of Donald Trump. The redesign triggered a popular backlash of passholders' covering his photo with stickers; the Park Service responded by updating its ban on defaced passes to include anything obscuring the front. The year also marked the Treasury's announcement that Trump's own signature would replace that of the treasurer on paper currency, another first for a president; the State Department’s issuance of a new passport design with a portrait of Trump, the first living president to appear on a U.S. passport, offered as an option to in-person applicants at the Washington, D.C., Passport Agency; and Florida Gov. Ron DeSantis's consent to renaming Palm Beach International Airport after Trump, a change the president had reportedly sought in 2020. Other measures bearing Trump’s name are Trump accounts, tax-advantaged investment accounts for American minors rolled out as part of the One Big Beautiful Bill Act; TrumpRx, a prescription drug website run by the federal government; and the Trump Gold Card, a program offering foreign nationals expedited U.S. residency in exchange for donations of $1 million or more to the Commerce Department and denounced by U.S. Sen.
Scott in 1951 published a protocol described as "the advent of the modern blood culture set". Scott's method involved inoculating blood into two rubber-sealed glass bottles; one for aerobes and one for anaerobes. The aerobic bottle contained trypticase soy broth and an agar slant, and the anaerobic bottle contained thioglycollate broth. The lysis-centrifugation method was introduced in 1917 by Mildred Clough, but it was rarely used in clinical practice until commercial systems were developed in the mid-1970s. Automated blood culture systems first became available in the 1970s. The earliest of these—the BACTEC systems, produced by Johnston Laboratories (now Becton Dickinson)—used culture broths containing nutrients labelled with radioactive isotopes. Microbes that fed on these substrates would produce radioactive carbon dioxide, and growth could be detected by monitoring its concentration. Before this technique was applied to blood cultures, it had been proposed by NASA as a method for detecting life on Mars. Throughout the 1970s and 80s several manufacturers attempted to detect microbial growth by measuring changes in the electrical conductivity of the culture medium, but none of these methods were commercially successful. A major issue with the early BACTEC systems was that they produced radioactive waste, which required special disposal procedures, so in 1984 a new generation of BACTEC instruments was released that used spectrophotometry to detect CO2.
Protein design is the rational design of new protein molecules to design novel activity, behavior, or purpose, and to advance basic understanding of protein function. Proteins can be designed from scratch (de novo design) or by making calculated variants of a known protein structure and its sequence (termed protein redesign). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or artificial gene synthesis. Rational protein design dates back to the mid-1970s. Recently, however, there were numerous examples of successful rational design of water-soluble and even transmembrane peptides and proteins, in part due to a better understanding of different factors contributing to protein structure stability and development of better computational methods.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.